The Chemours Company
CC Basic Materials Specialty Chemicals
The Chemours Company’s revenue for fiscal 2025 (year ended December 2025) was $5.8 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue fell 1.49%, EPS grew 28.7%, free cash flow grew 128.0% and total debt fell 6.47%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CC
The Chemours Company (CC) P/E ratio
The Chemours Company has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 954× (March 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 30.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 8.4× | (7.01%) |
| FY2021 | 9.0× | (51.10%) |
| FY2020 | 18.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 5.0× | (60.65%) |
| FY2017 | 12.8× | (97.59%) |
| FY2016 | 531× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MTX Minerals Technologies Inc. compare | n/m |
| SCL Stepan Company compare | n/m |
| CC The Chemours Company | n/m |
| FUL H. B. Fuller Company compare | 14.1× |
| IOSP Innospec Inc. compare | 19.7× |
| KWR Quaker Houghton compare | 27.9× |
| WDFC WD-40 Company compare | 30.3× |
| HWKN Hawkins, Inc. compare | 33.8× |
| NGVT Ingevity Corporation compare | 45.3× |
| Specialty Chemicals industry median | 25.4× |
| Basic Materials sector median | 19.5× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)